Entrada Therapeutics Inc expected to post earnings of 12 cents a share - Earnings Preview

Entrada Therapeutics

08/05/2024 12:42

* Entrada Therapeutics Inc  TRDA.OQ   TRDA.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 6
(estimated) for the period ending June 30 2024
    * The Boston Massachusetts-based  company is expected to
report a
74.4% increase in revenue to $31.681 million from $18.17 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Entrada Therapeutics Inc
is
for earnings of 12 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 11.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Entrada
Therapeutics Inc is $21.00​, above​ its last closing price
of $13.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.61       -0.59      0.68      Beat    214.5
 Jan. 1 2024   0.12        -0.17      -0.29     Missed  238.6
 Jan. 1 0001   -0.76       -0.74      1.02      Beat    238.6​
 Jan. 1 0001   -0.68       -0.69      -0.78     Missed  -13
 ​​Mar.        0.90        0.97       -0.21     Missed  -121.7
 31 2023                                                
 Jan. 1 0001   -0.83       -0.83      -0.79     Beat    4.4​
 Sep. 30 2022              -0.76      -0.80     Missed  -5.3
 Jun. 30 2022              -0.72      -0.74     Missed  -2.2
 This summary was machine generated May 8 at 11:42 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)